Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DTSL .0003's getting tapped, thin, will run
DTSL .0002's getting hammered, almost gone
DTSL the train is getting loaded
DTSL nice action, Ask a lot thinner
DTSL unusual trades going through, on watch
NSPT 10 mil slap @ .0002, Bid growing
DTSL grabbed some, getting nice hits
DTSL volume picking up last two day, on watch
NSPT low float, grabbed a few yesterday
PRMO .0003's falling
PRMO .0002's going
PRMO larger blocks hitting @.0002
CPOW someone continues to load up on the .0002's
CPOW .0002's are falling, BID growing
HIMR someone trying to give it a jump start
HIMR accumulation for some reason, .0002's up
CUBV share reduction and merger news, loading zone here
KGRI 5mil hit, got a pulse, thin
KGRI nice L2, thin
GMGI big hits @.0004
GMGI loading zone
GMGI big hits and volume, entered bitcoin market in January
GMGI bitcoin market, big hits and volume
ELRA big buys, .0002 up, Bid growing
SAFS .0003 getting hammered, a lot of volume lately
ECOS Current Report Filing (8-k): https://ih.advfn.com/p.php?pid=nmona&article=77053080
ECOS News: ECOS To Introduce a New Source of Biomass Fuel
MORTON GROVE, Ill. , March 28, 2018 /PRNewswire/ -- As demands for energy rise, EcoloCap (OTC:ECOS) can meet those demands by the production of reliable green energy sources.
The ECOS R&D department has tested the organic output of the BioART process and has established that it has an application as a clean burning, carbon-neutral fuel. The new application has almost the energy of coal and is free from the vagaries that effect other types of renewable energy.
With our new product, we plan to sell our biomass (biological material originating from once living plants or animals) to the power plants that utilize plant-based biomass as a fuel source.
According to the Biomass Power Association , there are 80 biomass plants in 20 states that make up the $1 billion renewable energy industry. The industry created more than 14,000 jobs nationwide with most of the facilities located in rural communities.
Nationwide, the biomass power industry diverts more about 22 million tons of waste wood annually and reuses it to create power, generating roughly 15 million megawatt hours per year.
James Kwak , ECOS CEO, states, "Biomass power plants are one of the cleanest and most reliable ways to convert excess biomass material into energy. It is also one of the most environmentally beneficial; biomass energy plants have a net negative emission of greenhouse gases. The use of ECOS Biomass will substantially reduce the higher levels of greenhouse gases, which includes, carbon dioxide, methane, and nitrous oxide as a result burning carbon-based fuels. Our biomass from the BioART process is just one of many reusable energy products we are researching and developing. We are excited for the future."
About EcoloCap
The EcoloCap sustainable, compost technology redirects all organic waste into a valuable byproduct. The byproduct includes organic fertilizers, chicken, fish feed, or biomass in the form of a dry powder or pellet that can be efficiently stored, transported, and spread.
This press release may contain statements of a forward-looking nature regarding future events. These statements are only predictions, and actual events may differ materially. Please refer to documents that EcoloCap Solutions Inc. files from time to time with the Securities and Exchange Commission for a discussion of certain factors that could cause actual results to differ materials from those contained in the forward-looking statements.
Visit EcoloCap.com for more information.
Contact: Joseph Mure, 1-312-585-6670,
jm@ecolocap.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/ecos-to-introduce-a-new-source-of-biomass-fuel-300621074.html
SOURCE EcoloCap
GBBT 5 mil blocks hitting @ .0004
GBBT huge buys
EPXY more filings
INCC News this morning: ANP Acquisition Translates into Future Growth
SARASOTA, Fla., March 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- International Consolidated Companies, Inc. (OTC:INCC), is happy to provide detail to the shareholders regarding the American Nutritional Products Inc. (“ANP”) Acquisition.
American Nutritional Products, Inc. certifications
INCC is proud to be moving forward with acquiring ANP., a Carson City, Nevada nutraceutical manufacturer. Owned by the former owners of Vitamin Research Products (“VRP”), Rob and Maria Watson built the NSF cGMP Organic 55 thousand square foot facility to house the VRP and Complementary Prescriptions (“CP”) physician’s brands. Combined they have over 50 plus years of industry experience. In 2010 they sold the brands with revenues exceeding $25 million with the highest retention rate the buyers had ever seen (80 plus percent).
In 2016 after the buyers failed and vacated the building, Maria Watson made the decision to "start over".
A little background on Maria. Tragically in 1987 Maria Watson lost her 3-year-old son Joshua to a drunk driver. After three years of horrific depression she was introduced to an amino acid formula, which changed her life and put her on a mission to help others. She immersed herself in research, learning everything she could about nutrients and their effects on the mind and body. For Maria, this is a passion NOT a job!
Rob was ready to retire … Maria lasted three weeks in retirement! Unable to sit still she accepted a 2 year position as CMO (Chief Marketing Officer) for Neogenis now Human N and was part of the team that created “SuperBeets”.
The facility outfitted with breakthrough technologies, cutting-edge tools, and the original team of formulators was regrouped and was ready with the name “American Nutritional Products Inc.”.
ANP capabilities include contract manufacturing and co packing of:
Powders;
Capsules;
Creams
Lotions;
Liquids;
Tinctures;
Vape oils
This acquisition will provide Vertical integration between the BluDog brand and manufacturing.
http://www.anp-nv.com/about/
In addition to
www.BluDogProducts.com INCC will own, post acquisition, the following brands:
https://www.perfectvitaminproducts.com/
https://www.scientifichealthsolutions.com/
https://www.fullspectrumhemp.com/
“We are excited about integrating and acquiring more nutraceutical co-packers as we venture off into a traditional roll up. Between the economies of scale and the natural symbiosis of our brands and manufacturing I believe we have a real tiger by the tail!” said Antonio Uccello, CEO BluDog Products LLC .
BluDog Products is strategically introducing a water-soluble CBD oil super food and wellness drinks (with an extended release formulation) that are easily absorbed. Using a licensed, patented CBD delivery system BluDog’s CBD products are an alternative over-the-counter therapeutic option to help relieve post-sports in?ammation as well as promote relaxation and well-being. BluDog’s CBD products interact naturally with the body’s anti-in?ammatory system without any known side e?ects.
International Consolidated Companies (INCC) was founded in 2002. INCC is focused on acquiring and growing businesses that offer innovation, quality, and cost-efficient Cannabis technologies.
Forward-looking disclaimer
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risk and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements to be materially different from the statements made herein.
More Information: Antonio F. Uccello, INCC; (720-460-0734) (baltic38dp@me.com), www.BluDogProducts.com , @BluDogProducts
SOURCE: International Consolidated Companies, Inc.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/42aaf92e-fd99-4655-b09d-3a8c5c887155
NPWZ .0004 hitting, thin
LGBS looks like reversal, .0004 up, thin
HIMR 2 mil buy now
HIMR 1 mil buy at .0002, tap tap
HIMR more taps, only 66 mil at .0002
HIMR .0002 tapped
MDIN .0002 starting
RCHA NEWS: Rich Pharmaceuticals' Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin's Lymphoma
BEVERLY HILLS, CA , March 14, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc . (OTC: RCHA), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, announced today the potential for using its drug RP-323 (TPA) in the treatment of Hodgkin's lymphoma.
Hodgkin’s lymphoma is a cancer that is found most frequently in two different age groups: 15 – 35 and over 55. It occurs in both sexes although it is more common in males. Cancer cells invade and destroy the architecture of the lymph nodes and infiltrate the liver, the spleen or other parts of the body. In the U.S., more than 100,000 people suffer from Hodgkin's lymphoma.
"A phase I clinical trial conducted at The Cancer Institute of New Jersey have shown that RP-323 treatment reduced a palpable tumor mass after three weeks in a patient with Hodgkin's lymphoma. We look forward to being able to commence clinical trials in the future to prove that using RP-323 alone or in combination with other anticancer agents will have significant therapeutic activity against Hodgkin's lymphoma,” said Rich Pharmaceuticals CEO, Ben Chang . "Clinical studies in China have also demonstrated that IV administration of RP-323 resulted in remission in some patients with myelocytic leukemia."
About Rich Pharmaceuticals :
Rich Pharmaceuticals, Inc. is a clinical-stage Biopharmaceutical Company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML), Hodgkin's Lymphoma (HL) and other blood related diseases. It is currently in Phase 1/2 clinical trials for the treatment of AML and HL. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Learn more at
www.richpharmaceuticals.com.
Forward-Looking Statements:
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to commence clinical trials and to continue to pursue our business and product development plans, including the business and product development plans contained in this news release, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC , available at www.sec.gov.
Contact:
Paul Knopick
Pknopick@eandecommunications.com
940.262.3584